Showing results (201-210 of 3,174) with videos related to

Sort By:
Pageof 318
Plos One|March 22, 2013
Functional enhancement of AT1R potency in the presence of the TPαR is revealed by a comprehensive 7TM receptor co-expression screenJonas Tind Hansen, Christina Lyngsø, Tobias Speerschneider, et al.
Molecular Pharmacology|September 9, 2006
Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activationTracy A Spalding, Jian-Nong Ma, Thomas R Ott, et al.
Biochemical Pharmacology|September 12, 2001
Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoidL D Recht, R Salmonsen, R Rosetti, et al.
Circulation|January 1, 1995
Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning?R A Kloner, T Shook, K Przyklenk, et al.
Journal of Medicinal Chemistry|August 30, 2008
Discovery of potent and selective small-molecule PAR-2 agonistsJimmi Gerner Seitzberg, Anne Eeg Knapp, Birgitte Winther Lund, et al.
The Journal of Pediatrics|August 1, 1988
Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndromeR G Rosenfeld, R L Hintz, A J Johanson, et al.
Clinical Pharmacology and Therapeutics|August 1, 1987
Trazodone kinetics: effect of age, gender, and obesityD J Greenblatt, H Friedman, E S Burstein, et al.
Neuroscience Letters|July 9, 2018
A subtype-specific neuropeptide FF receptor antagonist attenuates morphine and nicotine withdrawal syndrome in the ratDavid H Malin, Mallori M Henceroth, Joanne Elayoubi, et al.
Ophthalmology and Therapy|October 9, 2020
Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle GlaucomaConstance O Okeke, Eitan S Burstein, Valerie Trubnik, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2026
Nonclinical characterization of ACP-204, a novel selective serotonin receptor subtype 2A receptor inverse agonistEthan S Burstein, Roger Olsson, Niklas Skold, et al.
Pageof 318